Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial

Ann Oncol. 2016 Nov;27(11):2137-2138. doi: 10.1093/annonc/mdw298. Epub 2016 Aug 8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung*
  • Humans
  • Lung Neoplasms
  • Neoplasm Recurrence, Local
  • Probiotics*
  • Quinazolinones

Substances

  • Quinazolinones
  • dacomitinib